Lundbeck
HLUN-B.CO
#2744
Rank
NZ$10.97 B
Marketcap
NZ$11.06
Share price
-0.80%
Change (1 day)
20.42%
Change (1 year)
Lundbeck is a Danish pharmaceutical company that produces various pharmaceutical products and has the indications schizophrenia, depression, Parkinson's disease and sleep disorders.

Earnings for Lundbeck (HLUN-B.CO)

Earnings in 2026 (TTM): NZ$1.45 Billion

According to Lundbeck's latest financial reports the company's current earnings are NZ$4.00 Billion. In 2025 the company made an earning of NZ$1.31 Billion, an increase over its 2024 earnings that were of NZ$0.95 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Lundbeck from 2009 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.45 B10.86%
2025 NZ$1.31 B37.43%
2024 NZ$0.95 B25.74%
2023 NZ$0.76 B21.77%
2022 NZ$0.62 B31.57%
2021 NZ$0.47 B-4.61%
2020 NZ$0.49 B-45.06%
2019 NZ$0.90 B-34.04%
2018 NZ$1.37 B12.83%
2017 NZ$1.21 B93.99%
2016 NZ$0.62 B-137.28%
2015 -NZ$1.69 Billion-1246.24%
2014 NZ$0.14 B-72.36%
2013 NZ$0.53 B4.38%
2012 NZ$0.50 B-55.18%
2011 NZ$1.13 B5.65%
2010 NZ$1.07 B-5.9%
2009 NZ$1.14 B